We work in four principles (predictive, preventive, personalised, participatory), measure what we do, and rely on robust clinical evidence. This page lays out exactly how.
The four "P" of modern longevity medicine (after Leroy Hood) — our methodological frame.
Biomarker and omics-based diagnostics detect risks years before they become clinical — from Lp(a) through NMR metabolomics to the epigenetic clock.
Evidence: Hood L et al., Nat Rev Cancer 2013 — Systems medicine and personalized health (PMID: 23839249).
We intervene before pathology develops. Lifestyle optimisation combined with targeted substitution (vitamin D, magnesium, B-complex) and IV protocols demonstrably reduces cardiovascular and metabolic risk.
Evidence: Lichtenstein AH et al., Circulation 2021 — Dietary guidance to improve cardiovascular health (PMID: 34724806).
Genotype (MTHFR, COMT, ApoE), phenotype (blood tests, wearables), behaviour and preference converge into an individual plan. No protocol is a stencil.
Evidence: Topol EJ, Nature Med 2019 — High-performance medicine: the convergence of human and AI (PMID: 30617339).
The patient is an active co-author. Findings are shared, decisions made jointly, lifestyle is accompanied — not prescribed.
Evidence: Hood L, Auffray C, Genome Med 2013 — Participatory medicine (PMID: 24050519).
A selection of values that appear in our reports — with rationale and target range. Full panels are tailored individually.
Direct particle count of all atherogenic lipoproteins — more sensitive than LDL-C alone.
Genetic high-risk marker; measure once in life.
Sterile low-grade inflammation — driver of inflammaging.
Mean glucose of the last 90 days; early indicator of metabolic drift.
Insulin resistance often visible years before HbA1c shifts.
Pleiotropic effects — immune, muscle, mood.
Predictor for cardiovascular mortality and cognitive decline.
Functional marker of methylation (B12, B6, folate).
Iron stores; very high (>300) and very low (<50) both problematic.
Strongest prognostic marker for all-cause mortality (JAMA 2018).
We're transparent between clinically established standard, well-supported adjunct, and experimental off-label status. All study PMIDs are verifiable via PubMed.
Activates mitochondrial energy production and NAD+-dependent repair enzymes (PARPs, sirtuins). Clinical use in chronic fatigue and post-viral syndromes.
Martens CR et al., Nat Commun 2018 — Chronic NR supplementation increases NAD+ (PMID: 29599478) · Dollerup OL et al., Diabetes 2020 — NR in obese men with insulin resistance (PMID: 31882547).
Red / near-infrared light activates cytochrome c oxidase, raises ATP production and modulates inflammation. Established MASCC guideline in oral mucositis; growing evidence in wound healing and skin quality.
Hamblin MR, AIMS Biophys 2017 — Mechanisms and applications of photobiomodulation (PMID: 28748217).
60-session protocol in healthy adults >64 showed telomere extension of ~20 % and reduction in senescent cells.
Hachmo Y et al., Aging 2020 — HBOT increases telomere length (PMID: 33206062).
Mesenchymal stem-cell exosomes deliver paracrine regenerative signals without cell transplantation. Clinical evidence grows in skin regeneration, wound healing, tendinopathy.
Phinney DG, Pittenger MF, Stem Cells 2017 — MSC-derived exosomes in regenerative medicine (PMID: 28432717).
Top-quartile VO₂max reduces all-cause mortality by 80 % vs lowest quartile — bigger than the effects of smoking or diabetes.
Mandsager K et al., JAMA Netw Open 2018 — Cardiorespiratory fitness and long-term mortality (PMID: 30646433).
Gold standard against sarcopenia and frailty; combined reduces all-cause mortality in older adults.
Morton RW et al., Br J Sports Med 2018 — Protein supplementation and resistance training (PMID: 28698222).
60–90 minutes, no commitment. We listen before we recommend.